

John Peter Perentesis

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4424944/publications.pdf>

Version: 2024-02-01

109
papers

3,421
citations

147801

31
h-index

155660

55
g-index

110
all docs

110
docs citations

110
times ranked

4969
citing authors

#	ARTICLE	IF	CITATIONS
1	The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia. <i>Leukemia</i> , 2022, 36, 438-451.	7.2	13
2	Inhibition of the RacGEF VAV3 by the small molecule IODVA1 impedes RAC signaling and overcomes resistance to tyrosine kinase inhibition in acute lymphoblastic leukemia. <i>Leukemia</i> , 2022, 36, 637-647.	7.2	5
3	Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia. <i>Science Translational Medicine</i> , 2022, 14, eabb7695.	12.4	13
4	US News & World Report and quality metrics: Inclusion of sickle cell disease is a matter of equity. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29679.	1.5	2
5	Visual outcomes following everolimus targeted therapy for neurofibromatosis type 1-associated optic pathway gliomas in children. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28833.	1.5	9
6	Differential transcriptome response to proton versus X-ray radiation reveals novel candidate targets for combinatorial PT therapy in lymphoma. <i>Radiotherapy and Oncology</i> , 2021, 155, 293-303.	0.6	5
7	A POETIC Phase II study of continuous oral everolimus in recurrent, radiographically progressive pediatric low-grade glioma. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28787.	1.5	17
8	FLASH Proton Pencil Beam Scanning Irradiation Minimizes Radiation-Induced Leg Contracture and Skin Toxicity in Mice. <i>Cancers</i> , 2021, 13, 1012.	3.7	109
9	PD-1 Inhibition Enhances Blinatumomab Response in a UCB/PDX Model of Relapsed Pediatric B-Cell Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2021, 11, 642466.	2.8	14
10	Deep learning to identify and predict cardiotoxicities of anticancer drugs.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15012-e15012.	1.6	0
11	V2 Trial: A phase I study of venetoclax and CPX-351 for young patients with relapsed/refractory acute leukemia.. <i>Journal of Clinical Oncology</i> , 2021, 39, TPS7052-TPS7052.	1.6	1
12	Treatment of posttransplant lymphoproliferative disorder with poor prognostic features in children and young adults: Short-course EPOCH regimens are safe and effective. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29126.	1.5	5
13	An open invitation to join the Pediatric Proton/Photon Consortium Registry to standardize data collection in pediatric radiation oncology. <i>British Journal of Radiology</i> , 2020, 93, 20190673.	2.2	24
14	Whole brain proton irradiation in adult Sprague Dawley rats produces dose dependent and non-dependent cognitive, behavioral, and dopaminergic effects. <i>Scientific Reports</i> , 2020, 10, 21584.	3.3	5
15	Targeting Refractory Sarcomas and Malignant Peripheral Nerve Sheath Tumors in a Phase I/II Study of Sirolimus in Combination with Ganetespib (SARC023). <i>Sarcoma</i> , 2020, 2020, 1-8.	1.3	33
16	A phase II study of continuous oral mTOR inhibitor everolimus for recurrent, radiographic-progressive neurofibromatosis type 1-associated pediatric low-grade glioma: a Neurofibromatosis Clinical Trials Consortium study. <i>Neuro-Oncology</i> , 2020, 22, 1527-1535.	1.2	45
17	Targeting AML-associated FLT3 mutations with a type I kinase inhibitor. <i>Journal of Clinical Investigation</i> , 2020, 130, 2017-2023.	8.2	23
18	Methylation profiling of hypomethylating agent response and treatment failure in pediatric and young adult MDS/AML.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22502-e22502.	1.6	0

#	ARTICLE	IF	CITATIONS
19	Targeting Sporadic and Neurofibromatosis Type 1 (NF1) Related Refractory Malignant Peripheral Nerve Sheath Tumors (MPNST) in a Phase II Study of Everolimus in Combination with Bevacizumab (SARC016). Sarcoma, 2019, 2019, 1-8.	1.3	45
20	Overcoming adaptive therapy resistance in AML by targeting immune response pathways. Science Translational Medicine, 2019, 11, .	12.4	54
21	Improved chemotherapy modeling with RAG-based immune deficient mice. PLoS ONE, 2019, 14, e0225532.	2.5	21
22	V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia. Blood, 2019, 134, 3830-3830.	1.4	1
23	Overcoming Adaptive Therapy Resistance in AML By Targeting Immune Response Pathways. Blood, 2019, 134, 3934-3934.	1.4	0
24	Viral surveillance using PCR during treatment of AML and ALL. Pediatric Blood and Cancer, 2018, 65, e26752.	1.5	9
25	Proton therapy for pediatric malignancies: Fact, figures and costs. A joint consensus statement from the pediatric subcommittee of PTCOG, PROS and EPTN. Radiotherapy and Oncology, 2018, 128, 44-55.	0.6	46
26	An Update From the Pediatric Proton Consortium Registry. Frontiers in Oncology, 2018, 8, 165.	2.8	37
27	miR-196b target screen reveals mechanisms maintaining leukemia stemness with therapeutic potential. Journal of Experimental Medicine, 2018, 215, 2115-2136.	8.5	20
28	Predicting Drug Response and Novel Therapeutic Candidates Using Signatures of Molecular Alterations in Hematologic Malignancies. Blood, 2018, 132, 2219-2219.	1.4	1
29	Cancer Cell Metabolism: Implications for X-ray and Particle Radiation Therapy. International Journal of Particle Therapy, 2018, 5, 40-48.	1.8	8
30	KLF5 controls glutathione metabolism to suppress p190-BCR-ABL+ B-cell lymphoblastic leukemia. Oncotarget, 2018, 9, 29665-29679.	1.8	6
31	A novel in vitro approach for the identification of exceptional responders in acute myeloid leukemia.. Journal of Clinical Oncology, 2018, 36, e19011-e19011.	1.6	0
32	A Phase I/Pilot Study of CPX-351 [Daunorubicin and Cytarabine Liposome for Injection (Vyxeos®)] for Children, Adolescents and Young Adults with Recurrent or Refractory Acute Leukemia. Blood, 2018, 132, 336-336.	1.4	0
33	In Vitro Approach for the Identification of Exceptional Responders in Acute Myeloid Leukemia. Blood, 2018, 132, 2212-2212.	1.4	0
34	Therapeutic Targeting of the Ubiquitin Conjugating Enzyme UBE2N in Myeloid Malignancies. Blood, 2018, 132, 4050-4050.	1.4	0
35	Population pharmacokinetics of temsirolimus and sirolimus in children with recurrent solid tumours: a report from the Children's Oncology Group. British Journal of Clinical Pharmacology, 2017, 83, 1097-1107.	2.4	14
36	A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111). Pediatric Blood and Cancer, 2017, 64, e26565.	1.5	11

#	ARTICLE	IF	CITATIONS
37	A comparison of safety and efficacy of cytotoxic versus molecularly targeted drugs in pediatric phase I solid tumor oncology trials. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26258.	1.5	12
38	Significant and Sustained Reduction in Chemotherapy Errors Through Improvement Science. <i>Journal of Oncology Practice</i> , 2017, 13, e329-e336.	2.5	8
39	Significant and sustained reduction in chemotherapy errors though improvement science.. <i>Journal of Clinical Oncology</i> , 2017, 35, 37-37.	1.6	2
40	Molecular signatures and responses to targeted therapies in over 300 relapsed and therapy-refractory young adult (AYA) and childhood cancers.. <i>Journal of Clinical Oncology</i> , 2017, 35, 11514-11514.	1.6	0
41	Large scale adverse event data mining for targeted therapies development.. <i>Journal of Clinical Oncology</i> , 2017, 35, 2538-2538.	1.6	0
42	Increasing Activities of Daily Living Is as Easy as 1-2-3. <i>Journal of Pediatric Oncology Nursing</i> , 2016, 33, 345-352.	1.5	13
43	A phase I/pilot study of CPX-351 for children, adolescents and young adults with recurrent or refractory hematologic malignancies.. <i>Journal of Clinical Oncology</i> , 2016, 34, 10541-10541.	1.6	6
44	SARC016: Phase II study of everolimus in combination with bevacizumab in sporadic and neurofibromatosis type 1 (NF1) related refractory malignant peripheral nerve sheath tumors (MPNST).. <i>Journal of Clinical Oncology</i> , 2016, 34, 11053-11053.	1.6	19
45	Pharmacogenomic prediction of treatment-induced severe lung toxicity in Hodgkin lymphoma (HL).. <i>Journal of Clinical Oncology</i> , 2016, 34, 7522-7522.	1.6	0
46	Age-Dependent Changes in Sirolimus Metabolite Formation in Patients With Neurofibromatosis Type 1. <i>Therapeutic Drug Monitoring</i> , 2015, 37, 395-399.	2.0	10
47	Pilot study of intravenous melphalan combined with continuous infusion L-cystathionine sulfoximine for children with recurrent neuroblastoma. <i>Pediatric Blood and Cancer</i> , 2015, 62, 1739-1746.	1.5	31
48	Increasing the efficiency of trial-patient matching: automated clinical trial eligibility Pre-screening for pediatric oncology patients. <i>BMC Medical Informatics and Decision Making</i> , 2015, 15, 28.	3.0	82
49	Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a Neurofibromatosis Clinical Trials Consortium phase II study. <i>Neuro-Oncology</i> , 2015, 17, 596-603.	1.2	118
50	A Phase I Study of Cixutumumab (IMC-A12) in Combination with Temsirolimus (CCI-779) in Children with Recurrent Solid Tumors: A Children's Oncology Group Phase I Consortium Report. <i>Clinical Cancer Research</i> , 2015, 21, 1558-1565.	7.0	20
51	Toxicity of Cancer Therapy in Adolescents and Young Adults (AYAs). <i>Seminars in Oncology Nursing</i> , 2015, 31, 216-226.	1.5	36
52	Next generation sequencing (NGS) to identify targetable recurring mutations and exceptional responders in relapsed and high-risk childhood and adolescent/young adult (AYA) malignancies.. <i>Journal of Clinical Oncology</i> , 2015, 33, 11011-11011.	1.6	0
53	Kidney Injury Molecule-1 and its association with delayed clearance and drug exposure in pediatric oncology patients treated with high dose methotrexate.. <i>Journal of Clinical Oncology</i> , 2015, 33, 10034-10034.	1.6	0
54	Pharmacogenetic variants associated with differential sirolimus clearance in pediatric patients.. <i>Journal of Clinical Oncology</i> , 2015, 33, 2562-2562.	1.6	0

#	ARTICLE	IF	CITATIONS
55	Sirolimus for nonâ€progressive NF1â€associated plexiform neurofibromas: An NF clinical trials consortium phase II study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 982-986.	1.5	73
56	A phase I trial of MKâ€2206 in children with refractory malignancies: A Children's Oncology Group study. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1246-1251.	1.5	35
57	Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. <i>Neuro-Oncology</i> , 2014, 16, 707-718.	1.2	93
58	AAML0523: A report from the Children's Oncology Group on the efficacy of clofarabine in combination with cytarabine in pediatric patients with recurrent acute myeloid leukemia. <i>Cancer</i> , 2014, 120, 2482-2489.	4.1	29
59	A Phase 2 study of bortezomib combined with either idarubicin/cytarabine or cytarabine/etoposide in children with relapsed, refractory or secondary acute myeloid leukemia: A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2014, 61, 1754-1760.	1.5	44
60	A phase 1 study of the c-Met inhibitor tivantinib (ARQ 197, IND#112603) in children with relapsed or refractory solid tumors: A Childrenâ€™s Oncology Group study.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2627-2627.	1.6	3
61	SARC023: Phase I/II trial of ganetespib in combination with sirolimus for refractory sarcomas and malignant peripheral nerve sheath tumors (MPNST).. <i>Journal of Clinical Oncology</i> , 2014, 32, TPS10603-TPS10603.	1.6	8
62	Low dose decitabine in very high risk relapsed or refractory acute myeloid leukaemia in children and young adults. <i>British Journal of Haematology</i> , 2013, 161, 406-410.	2.5	42
63	Phase I/II trial of clofarabine and cytarabine in children with relapsed/refractory acute lymphoblastic leukemia (AAML0523): A report from the Children's Oncology Group. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1141-1147.	1.5	20
64	Children's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia. <i>Pediatric Blood and Cancer</i> , 2013, 60, 964-971.	1.5	70
65	Population Pharmacokinetics of Sirolimus in Pediatric Patients With Neurofibromatosis Type 1. <i>Therapeutic Drug Monitoring</i> , 2013, 35, 332-337.	2.0	27
66	Differences in outcomes of newly diagnosed acute myeloid leukemia for adolescent/young adult and younger patients. <i>Cancer</i> , 2013, 119, 4162-4169.	4.1	66
67	Children's Oncology Group's 2013 blueprint for research: Adolescent and young adult oncology. <i>Pediatric Blood and Cancer</i> , 2013, 60, 1055-1058.	1.5	52
68	Genomic Characterization Of Histiocytic Lesions Following Pediatric T-Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2013, 122, 4940-4940.	1.4	0
69	Ras-Driven Transcriptome Analysis Identifies Aurora Kinase A as a Potential Malignant Peripheral Nerve Sheath Tumor Therapeutic Target. <i>Clinical Cancer Research</i> , 2012, 18, 5020-5030.	7.0	60
70	Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway. <i>Journal of Clinical Oncology</i> , 2012, 30, 2919-2928.	1.6	188
71	Vav3 collaborates with p190-BCR-ABL in lymphoid progenitor leukemogenesis, proliferation, and survival. <i>Blood</i> , 2012, 120, 800-811.	1.4	43
72	A Phase 2 Study of Bortezomib Combined with Reinduction Chemotherapy in Children and Young Adults with Recurrent, Refractory or Secondary Acute Myeloid Leukemia: A Children's Oncology Group (COG) Study. <i>Blood</i> , 2012, 120, 3580-3580.	1.4	4

#	ARTICLE	IF	CITATIONS
73	A phase I trial of IMC A12 and temsirolimus in children with refractory solid tumors: A Children's Oncology Group study.. Journal of Clinical Oncology, 2012, 30, 9541-9541.	1.6	0
74	A phase I trial of MK 2206 in children with refractory solid tumors: A Children's Oncology Group study.. Journal of Clinical Oncology, 2012, 30, 9581-9581.	1.6	0
75	Long-term complications after staging laparotomy for Hodgkin's lymphoma.. Journal of Clinical Oncology, 2012, 30, e20007-e20007.	1.6	0
76	AAML0523: A Report From the Children's Oncology Group On the Efficacy of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Myeloid Leukemia. Blood, 2012, 120, 3604-3604.	1.4	0
77	Unrelated Donor Bone Marrow Transplantation for Myelodysplastic Syndrome in Children. Biology of Blood and Marrow Transplantation, 2011, 17, 723-728.	2.0	26
78	Severe Allergic Reactions to Thiol-based Cytoprotective Agents Mesna and Amifostine in a Child With a Supratentorial Primitive Neuroectodermal Tumor. Journal of Pediatric Hematology/Oncology, 2011, 33, e250-e252.	0.6	7
79	Natural history of transient myeloproliferative disorder clinically diagnosed in Down syndrome neonates: a report from the Children's Oncology Group Study A2971. Blood, 2011, 118, 6752-6759.	1.4	182
80	Tribute: The American Society of Pediatric Hematology/Oncology (ASPHO), 2011 Distinguished Career Award goes to Dr. William G. Woods. Pediatric Blood and Cancer, 2011, 56, 895-896.	1.5	0
81	Treatment of Acute Myeloid Leukemia. Pediatric Oncology, 2011, , 121-160.	0.5	1
82	Phase I trial of two schedules of vincristine, oral irinotecan, and temozolomide (VOIT) for children with relapsed or refractory solid tumors: A Children's Oncology Group phase I consortium study. Pediatric Blood and Cancer, 2010, 54, 538-545.	1.5	68
83	MDM2 polymorphism increases susceptibility to childhood acute myeloid leukemia: A report from the Children's Oncology Group. Pediatric Blood and Cancer, 2010, 55, 248-253.	1.5	23
84	Oxidant Pathway Functional Polymorphisms Influence the Risk of Myeloid Leukemia/Transient Myeloproliferative Disorder In Children with Down Syndrome.. Blood, 2010, 116, 1680-1680.	1.4	0
85	Pediatric Experience with Low Dose Decitabine In Very High Risk Relapsed AML.. Blood, 2010, 116, 1070-1070.	1.4	41
86	Phase I study of paclitaxel with standard dose ifosfamide in children with refractory solid tumors: A Pediatric Oncology Group study (POG 9376). Pediatric Blood and Cancer, 2009, 52, 346-350.	1.5	16
87	Cytidine deaminase genotype and toxicity of cytosine arabinoside therapy in children with acute myeloid leukemia. British Journal of Haematology, 2009, 144, 388-394.	2.5	42
88	AAML0523: A Report From the Children's Oncology Group On the Safety of Clofarabine in Combination with Cytarabine in Pediatric Patients with Relapsed Acute Leukemia.. Blood, 2009, 114, 3076-3076.	1.4	4
89	Pathway Based Evaluation of Cytarabine Pharmacogenetics in Children with Acute Myeloid Leukemia.. Blood, 2009, 114, 2610-2610.	1.4	0
90	FAS Promoter Polymorphism: Outcome of Childhood Acute Myeloid Leukemia. A Children's Oncology Group Report. Clinical Cancer Research, 2008, 14, 7896-7899.	7.0	7

#	ARTICLE	IF	CITATIONS
91	Effective <i>in vivo</i> targeting of the mammalian target of rapamycin pathway in malignant peripheral nerve sheath tumors. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 1237-1245.	4.1	130
92	XPD Lys751Gln polymorphism in the etiology and outcome of childhood acute myeloid leukemia: a Children's Oncology Group report. <i>Blood</i> , 2006, 107, 39-45.	1.4	31
93	Ethnicity and survival in childhood acute myeloid leukemia: a report from the Children's Oncology Group. <i>Blood</i> , 2006, 108, 74-80.	1.4	117
94	Translocation (8;18;16)(p11;q21;p13). A new variant of t(8;16)(p11;p13) in acute monoblastic leukemia: case report and review of the literature. <i>Cancer Genetics and Cytogenetics</i> , 2006, 165, 75-78.	1.0	7
95	Renal Carcinomas With the t(6;11)(p21;q12). <i>American Journal of Surgical Pathology</i> , 2005, 29, 230-240.	3.7	279
96	XRCC1 and glutathione-S-transferase gene polymorphisms and susceptibility to radiotherapy-related malignancies in survivors of Hodgkin disease. <i>Cancer</i> , 2004, 101, 1463-1472.	4.1	61
97	Treating children with chronic myeloid leukemia in the Imatinib era: A therapeutic dilemma?. <i>Medical and Pediatric Oncology</i> , 2003, 41, 115-117.	1.0	15
98	Osteosarcoma in the first decade of life. <i>Medical and Pediatric Oncology</i> , 2003, 41, 480-483.	1.0	34
99	Results of Treatment for Metastatic Osteosarcoma With Neoadjuvant Chemotherapy and Surgery. <i>Clinical Orthopaedics and Related Research</i> , 2002, 397, 240-247.	1.5	60
100	Glutathione S-transferase genotypes, genetic susceptibility, and outcome of therapy in childhood acute lymphoblastic leukemia. <i>Blood</i> , 2002, 100, 67-71.	1.4	112
101	Recombinant Fusion Toxins Directed Against the Human Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Receptor. , 2001, 166, 31-53.		2
102	Targeted Therapies for High-Risk Acute Myeloid Leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2001, 15, 677-701.	2.2	8
103	Glutathione S-Transferase Polymorphisms and Outcome of Chemotherapy in Childhood Acute Myeloid Leukemia. <i>Journal of Clinical Oncology</i> , 2001, 19, 1279-1287.	1.6	139
104	Genomic imprinting of H19 and insulin-like growth factor-2 in pediatric germ cell tumors. , 1999, 85, 1389-1394.		38
105	Genomic imprinting of H19 and insulin-like growth factor-2 in pediatric germ cell tumors. <i>Cancer</i> , 1999, 85, 1389-1394.	4.1	1
106	Coinheritance of α -thalassemia-1 and hemoglobin E/ β ⁰ -thalassemia: Practical implications for neonatal screening and genetic counseling. <i>Journal of Pediatrics</i> , 1998, 132, 863-865.	1.8	19
107	Granulocyte-Macrophage colony-Stimulating factor receptor-Targeted therapy of chemotherapy- and radiation-Resistant human myeloid leukemias. <i>Leukemia and Lymphoma</i> , 1997, 25, 247-256.	1.3	13
108	A Recombinant fusion toxin targeted to the granulocyte-Macrophage colony-Stimulating factor receptor. <i>Leukemia and Lymphoma</i> , 1997, 25, 257-270.	1.3	19

#	ARTICLE	IF	CITATIONS
109	Big babies and infant leukemia: a role for insulin-like growth factor-1?. Cancer Causes and Control, 1996, 7, 553-559.	1.8	108